<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ARWR Investment Thesis | Helix</title>
    <style>
        
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
            background: #f8fafc; color: #1e293b; line-height: 1.6;
        }
        .container { max-width: 1200px; margin: 0 auto; padding: 2rem; }

        /* Header */
        .header { background: linear-gradient(135deg, #0f172a 0%, #1e3a5f 100%);
            color: white; padding: 3rem; border-radius: 1rem; margin-bottom: 2rem; }
        .header h1 { font-size: 2.5rem; margin-bottom: 0.5rem; }
        .header .subtitle { opacity: 0.8; font-size: 1.1rem; }
        .header .meta { margin-top: 1rem; font-size: 0.9rem; opacity: 0.7; }

        /* Sections */
        .section { background: white; border-radius: 0.75rem; padding: 2rem;
            margin-bottom: 1.5rem; box-shadow: 0 1px 3px rgba(0,0,0,0.1); }
        .section-title { font-size: 1.5rem; font-weight: 700; color: #0f172a;
            border-bottom: 3px solid #0ea5e9; padding-bottom: 0.5rem; margin-bottom: 1.5rem; }
        .section-divider { font-size: 0.8rem; text-transform: uppercase; letter-spacing: 0.1em;
            color: #64748b; margin: 2rem 0 1rem; }

        /* Grid layouts */
        .grid-2 { display: grid; grid-template-columns: repeat(2, 1fr); gap: 1.5rem; }
        .grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 1.5rem; }
        @media (max-width: 768px) { .grid-2, .grid-3 { grid-template-columns: 1fr; } }

        /* Cards */
        .card { background: #f8fafc; border-radius: 0.5rem; padding: 1.25rem;
            border: 1px solid #e2e8f0; }
        .card-title { font-weight: 600; color: #0f172a; margin-bottom: 0.5rem; }
        .card-value { font-size: 1.75rem; font-weight: 700; color: #0ea5e9; }
        .card-label { font-size: 0.85rem; color: #64748b; }

        /* Pipeline cards */
        .pipeline-card { border-left: 4px solid #0ea5e9; }
        .pipeline-card.approved { border-left-color: #22c55e; }
        .pipeline-card.phase3 { border-left-color: #f59e0b; }
        .pipeline-card.phase2 { border-left-color: #8b5cf6; }
        .pipeline-card.phase1 { border-left-color: #64748b; }

        /* Status badges */
        .badge { display: inline-block; padding: 0.25rem 0.75rem; border-radius: 9999px;
            font-size: 0.75rem; font-weight: 600; text-transform: uppercase; }
        .badge-approved { background: #dcfce7; color: #166534; }
        .badge-phase3 { background: #fef3c7; color: #92400e; }
        .badge-phase2 { background: #ede9fe; color: #5b21b6; }
        .badge-phase1 { background: #f1f5f9; color: #475569; }
        .badge-recruiting { background: #dbeafe; color: #1e40af; }
        .badge-completed { background: #d1fae5; color: #065f46; }

        /* Tables */
        table { width: 100%; border-collapse: collapse; margin: 1rem 0; }
        th, td { padding: 0.75rem 1rem; text-align: left; border-bottom: 1px solid #e2e8f0; }
        th { background: #f8fafc; font-weight: 600; color: #475569; font-size: 0.85rem;
            text-transform: uppercase; letter-spacing: 0.05em; }
        tr:hover { background: #f8fafc; }

        /* Bull/Bear boxes - Satya Bio branding */
        .thesis-box { padding: 1.25rem; border-radius: 0; margin: 1rem 0; background: #ffffff; border: 1px solid #e5e5e0; }
        .thesis-bull { border-left: 3px solid #e07a5f; }
        .thesis-bear { border-left: 3px solid #1a2b3c; }
        .thesis-key { border-left: 3px solid #3b82f6; background: #eff6ff; }
        .thesis-label { font-weight: 700; margin-bottom: 0.5rem; }
        .thesis-bull .thesis-label { color: #e07a5f; }
        .thesis-bear .thesis-label { color: #1a2b3c; }
        .thesis-key .thesis-label { color: #1e40af; }

        /* Links */
        a { color: #0ea5e9; text-decoration: none; }
        a:hover { text-decoration: underline; }
        .source-link { font-size: 0.75rem; color: #64748b; }

        /* Trial details */
        .trial-detail { display: flex; gap: 2rem; flex-wrap: wrap; }
        .trial-metric { text-align: center; padding: 1rem; background: #f8fafc; border-radius: 0.5rem; }
        .trial-metric-value { font-size: 1.5rem; font-weight: 700; color: #0ea5e9; }
        .trial-metric-label { font-size: 0.8rem; color: #64748b; }

        /* Catalyst timeline */
        .catalyst-item { display: flex; gap: 1rem; padding: 1rem 0; border-bottom: 1px solid #e2e8f0; }
        .catalyst-date { min-width: 100px; font-weight: 600; color: #0f172a; }
        .catalyst-event { flex: 1; }
        .catalyst-asset { font-size: 0.85rem; color: #64748b; }

        /* Verified badge */
        .verified { display: inline-flex; align-items: center; gap: 0.25rem;
            font-size: 0.75rem; color: #22c55e; }
        .verified::before { content: 'âœ“'; }

        /* Print styles */
        @media print {
            .container { max-width: 100%; padding: 0; }
            .section { break-inside: avoid; box-shadow: none; border: 1px solid #e2e8f0; }
        }
        
    </style>
</head>
<body>
    <div class="container">
        
        <div class="header">
            <h1>ARWR Investment Thesis</h1>
            <div class="subtitle">Arrowhead Pharmaceuticals</div>
            <div class="meta">
                Lead Asset: Plozasiran (Approved (FCS) / Phase 3 (sHTG)) |
                Last Verified: 2026-02-02
            </div>
        </div>
        
        
        <div class="section">
            <h2 class="section-title">Executive Summary</h2>

            <p style="font-size: 1.1rem; margin-bottom: 1.5rem;">Clinical-stage biopharmaceutical company developing RNAi therapeutics using its proprietary TRiM platform</p>

            <div class="grid-3" style="margin-bottom: 2rem;">
                <div class="card">
                    <div class="card-label">Approved Products</div>
                    <div class="card-value">1</div>
                </div>
                <div class="card">
                    <div class="card-label">Phase 3 Programs</div>
                    <div class="card-value">3</div>
                </div>
                <div class="card">
                    <div class="card-label">Partnership Milestones</div>
                    <div class="card-value">$3.3B</div>
                    <div class="card-label" style="margin-top: 0.25rem;">Received: $835M</div>
                </div>
            </div>

            <div class="section-divider">Pipeline Summary</div>
            <div class="grid-2">
                
            <div class="card pipeline-card approved">
                <div style="display: flex; justify-content: space-between; align-items: start;">
                    <div class="card-title">Plozasiran (ARO-APOC3)</div>
                    <span class="badge badge-approved">Approved (FCS)</span>
                </div>
                <div style="color: #64748b; font-size: 0.9rem; margin: 0.5rem 0;">FCS, Severe Hypertriglyceridemia, Mixed Hyperlipid</div>
                <div style="font-weight: 600; color: #0ea5e9; margin: 0.5rem 0;">80% TG reduction (PALISADE), 83% pancreatitis risk reduction</div>
                <div style="display: flex; justify-content: space-between; font-size: 0.85rem; color: #64748b;">
                    <span>Partner: Amgen</span>
                    <span class="verified">FDA Verified</span>
                </div>
            </div>
            
            <div class="card pipeline-card phase2">
                <div style="display: flex; justify-content: space-between; align-items: start;">
                    <div class="card-title">Zodasiran (ARO-ANG3)</div>
                    <span class="badge badge-phase2">Phase 2</span>
                </div>
                <div style="color: #64748b; font-size: 0.9rem; margin: 0.5rem 0;">Mixed Dyslipidemia, HoFH, ASCVD Risk Reduction</div>
                <div style="font-weight: 600; color: #0ea5e9; margin: 0.5rem 0;">65% LDL-C reduction, 70% TG reduction</div>
                <div style="display: flex; justify-content: space-between; font-size: 0.85rem; color: #64748b;">
                    <span>Partner: Amgen</span>
                    
                </div>
            </div>
            
            <div class="card pipeline-card phase3">
                <div style="display: flex; justify-content: space-between; align-items: start;">
                    <div class="card-title">Fazirsiran (ARO-AAT)</div>
                    <span class="badge badge-phase3">Phase 3</span>
                </div>
                <div style="color: #64748b; font-size: 0.9rem; margin: 0.5rem 0;">Alpha-1 Antitrypsin Deficiency Liver Disease (AATD</div>
                <div style="font-weight: 600; color: #0ea5e9; margin: 0.5rem 0;">96% Z-AAT reduction, liver fibrosis improvement</div>
                <div style="display: flex; justify-content: space-between; font-size: 0.85rem; color: #64748b;">
                    <span>Partner: Takeda</span>
                    
                </div>
            </div>
            
            <div class="card pipeline-card phase1">
                <div style="display: flex; justify-content: space-between; align-items: start;">
                    <div class="card-title">ARO-INHBE</div>
                    <span class="badge badge-phase1">Phase 1</span>
                </div>
                <div style="color: #64748b; font-size: 0.9rem; margin: 0.5rem 0;">Obesity, Metabolic Dysfunction</div>
                <div style="font-weight: 600; color: #0ea5e9; margin: 0.5rem 0;">6-9% weight loss (Phase 1)</div>
                <div style="display: flex; justify-content: space-between; font-size: 0.85rem; color: #64748b;">
                    <span>Partner: Wholly-owned</span>
                    
                </div>
            </div>
            
            </div>

            <div class='section-divider'>Key Investment Debates</div><ul style='margin-left: 1.5rem;'><li style='margin-bottom: 0.5rem;'>Will Phase 3 sHTG trials (SHASTA-3/4/5) succeed and enable broad commercial launch in the much larger sHTG population?</li></ul>
        </div>
        
        
        <div class="section">
            <h2 class="section-title">Platform Technology: TRiM</h2>

            <div class="grid-2">
                <div>
                    <h3 style="margin-bottom: 1rem;">Technology Overview</h3>
                    <p>Arrowhead's Targeted RNAi Molecule (TRiM) platform enables tissue-specific
                    delivery of siRNA therapeutics. The platform uses proprietary ligand-targeting
                    chemistry to direct RNAi payloads to specific cell types.</p>

                    <h4 style="margin: 1.5rem 0 0.75rem;">Tissue Targeting Capabilities</h4>
                    <ul style="margin-left: 1.5rem;">
                        <li><strong>Liver (GalNAc)</strong> - Most advanced, multiple programs</li>
                        <li><strong>Lung (inhaled)</strong> - ARO-RAGE, ARO-MUC5AC</li>
                        <li><strong>Muscle</strong> - ARO-DUX4 (FSHD), ARO-DM1</li>
                        <li><strong>CNS</strong> - ARO-MAPT (Alzheimer's), ARO-ATXN2</li>
                    </ul>
                </div>
                <div>
                    <h3 style="margin-bottom: 1rem;">Competitive Advantages</h3>
                    <table>
                        <tr><th>Feature</th><th>ARWR (TRiM)</th><th>ALNY (GalNAc)</th><th>IONS (ASO)</th></tr>
                        <tr><td>Dosing Frequency</td><td>Quarterly</td><td>Quarterly-Annual</td><td>Weekly-Monthly</td></tr>
                        <tr><td>Tissue Targets</td><td>Liver, Lung, Muscle, CNS</td><td>Primarily Liver</td><td>Broad</td></tr>
                        <tr><td>Approved Products</td><td>1 (REDEMPLO)</td><td>5</td><td>5</td></tr>
                        <tr><td>Partnership Model</td><td>Ph1 then partner</td><td>Retained rights</td><td>Mixed</td></tr>
                    </table>

                    <h4 style="margin: 1.5rem 0 0.75rem;">Platform Validation</h4>
                    <p>REDEMPLO (plozasiran) approval in Nov 2025 validated TRiM platform.
                    Multiple Phase 3 programs across therapeutic areas.</p>
                </div>
            </div>
        </div>
        
        
        <div class="section">
            <h2 class="section-title">Plozasiran (ARO-APOC3)</h2>

            <div class="grid-2" style="margin-bottom: 1.5rem;">
                <div>
                    <table>
                        <tr><td style="font-weight: 600; width: 120px;">Target</td><td>APOC3</td></tr>
                        <tr><td style="font-weight: 600;">Stage</td><td>Approved (FCS) / Phase 3 (sHTG)</td></tr>
                        <tr><td style="font-weight: 600;">Indication</td><td>FCS, Severe Hypertriglyceridemia, Mixed Hyperlipidemia</td></tr>
                        <tr><td style="font-weight: 600;">Modality</td><td>RNAi (siRNA)</td></tr>
                        <tr><td style="font-weight: 600;">Dosing</td><td>Subcutaneous injection every 12 weeks (quarterly)</td></tr>
                    </table>
                </div>
                <div>
                    <h4 style="margin-bottom: 0.75rem;">Mechanism</h4>
                    <p style="font-size: 0.9rem; color: #475569;">Silences APOC3 mRNA in hepatocytes. APOC3 inhibits lipoprotein lipase. By reducing APOC3, plozasiran increases LPL activity, accelerating clearance of triglyceride-rich lipoproteins.</p>
                </div>
            </div>

            
            <div class="card" style="background: #ecfdf5; border: 1px solid #22c55e; margin-top: 1rem;">
                <div class="verified" style="font-size: 1rem; color: #166534; margin-bottom: 0.5rem;">
                    FDA Approved
                </div>
                <div><strong>Brand:</strong> REDEMPLO</div>
                <div><strong>Approval Date:</strong> 2025-11-18</div>
                <div><strong>Indication:</strong> Indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)</div>
                <div class="source-link">Source: <a href="https://api.fda.gov/drug/drugsfda.json" target="_blank">OpenFDA</a></div>
            </div>
            

            <div class="section-divider">Clinical Development</div>
            
        <table>
            <thead>
                <tr><th>NCT ID</th><th>Trial</th><th>Phase</th><th>Status</th><th>Result</th></tr>
            </thead>
            <tbody>
                
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT05089084" target="_blank">NCT05089084</a></td>
                <td>PALISADE</td>
                <td>Phase 3</td>
                <td><span class="badge badge-recruiting">Active Not Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">-80%</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT04720534" target="_blank">NCT04720534</a></td>
                <td>SHASTA-2</td>
                <td>Phase 2</td>
                <td><span class="badge badge-completed">Completed</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">-77% (Q12W)</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT06347003" target="_blank">NCT06347003</a></td>
                <td>SHASTA-3</td>
                <td>Phase 3</td>
                <td><span class="badge badge-recruiting">Active Not Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT06347016" target="_blank">NCT06347016</a></td>
                <td>SHASTA-4</td>
                <td>Phase 3</td>
                <td><span class="badge badge-recruiting">Active Not Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT06880770" target="_blank">NCT06880770</a></td>
                <td>SHASTA-5</td>
                <td>Phase 3</td>
                <td><span class="badge badge-recruiting">Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT06822790" target="_blank">NCT06822790</a></td>
                <td>SHASTA-10</td>
                <td>Phase 3</td>
                <td><span class="badge badge-recruiting">Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT04998201" target="_blank">NCT04998201</a></td>
                <td>MUIR</td>
                <td>Phase 2</td>
                <td><span class="badge badge-completed">Completed</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT06347133" target="_blank">NCT06347133</a></td>
                <td>MUIR-3</td>
                <td>Phase 3</td>
                <td><span class="badge badge-recruiting">Active Not Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            </tbody>
        </table>
        

            <div class="section-divider">Competitive Landscape</div>
            
        <table>
            <thead>
                <tr><th>Drug</th><th>Company</th><th>Mechanism</th><th>Stage</th><th>Efficacy</th><th>Differentiation</th></tr>
            </thead>
            <tbody>
                
            <tr>
                <td><strong>Volanesorsen (Waylivra)</strong></td>
                <td>Ionis/Sobi</td>
                <td>ASO targeting APOC3</td>
                <td>Approved (EU only)</td>
                <td>77% TG reduction</td>
                <td style="font-size: 0.85rem;">Plozasiran has better safety (no platelet issues), less frequent dosing (quarterly vs weekly)</td>
            </tr>
            
            <tr>
                <td><strong>Olezarsen</strong></td>
                <td>Ionis</td>
                <td>GalNAc-ASO targeting APOC3</td>
                <td>Approved (US, Dec 2024)</td>
                <td>~60% TG reduction</td>
                <td style="font-size: 0.85rem;">Both quarterly. Plozasiran shows higher TG reduction. Commercial race ongoing.</td>
            </tr>
            
            </tbody>
        </table>
        

            
            <div class="section-divider">Investment View</div>
            <div class="thesis-box thesis-bull">
                <div class="thesis-label">Bull Thesis</div>
                <p>First-in-class RNAi therapeutic for APOC3 with best-in-class 80% triglyceride reduction and durable quarterly dosing. FCS approval validates mechanism. sHTG represents 10x larger market (~500K US patients). SHASTA-3/4/5 trials ongoing for broader indications. Amgen partnership provides experienced CV sales force.</p>
            </div>
            <div class="thesis-box thesis-bear">
                <div class="thesis-label">Bear Thesis</div>
                <p>FCS is tiny orphan market (~3,000 US patients). sHTG faces competition from Ionis olezarsen. Amgen controls commercialization meaning majority economics flow to partner. No CV outcomes data yet.</p>
            </div>
            <div class="thesis-box thesis-key">
                <div class="thesis-label">Key Question</div>
                <p>Will Phase 3 sHTG trials (SHASTA-3/4/5) succeed and enable broad commercial launch in the much larger sHTG population?</p>
            </div>
            
        </div>
        
        <div class="section">
            <h2 class="section-title">Zodasiran (ARO-ANG3)</h2>

            <div class="grid-2" style="margin-bottom: 1.5rem;">
                <div>
                    <table>
                        <tr><td style="font-weight: 600; width: 120px;">Target</td><td>ANGPTL3</td></tr>
                        <tr><td style="font-weight: 600;">Stage</td><td>Phase 2/3</td></tr>
                        <tr><td style="font-weight: 600;">Indication</td><td>Mixed Dyslipidemia, HoFH, ASCVD Risk Reduction</td></tr>
                        <tr><td style="font-weight: 600;">Modality</td><td>RNAi (siRNA)</td></tr>
                        <tr><td style="font-weight: 600;">Dosing</td><td>Subcutaneous Q12W (quarterly)</td></tr>
                    </table>
                </div>
                <div>
                    <h4 style="margin-bottom: 0.75rem;">Mechanism</h4>
                    <p style="font-size: 0.9rem; color: #475569;">Silences ANGPTL3 which inhibits both LPL and endothelial lipase. Lowers both TG and LDL-C.</p>
                </div>
            </div>

            

            <div class="section-divider">Clinical Development</div>
            
        <table>
            <thead>
                <tr><th>NCT ID</th><th>Trial</th><th>Phase</th><th>Status</th><th>Result</th></tr>
            </thead>
            <tbody>
                
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT04832971" target="_blank">NCT04832971</a></td>
                <td>ARCHES-2</td>
                <td>Phase 2</td>
                <td><span class="badge badge-completed">Completed</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">-55%</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT05217667" target="_blank">NCT05217667</a></td>
                <td>Gateway</td>
                <td>Phase 2</td>
                <td><span class="badge badge-recruiting">Active Not Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT07037771" target="_blank">NCT07037771</a></td>
                <td>Zodasiran Phase 3 HoFH</td>
                <td>Phase 3</td>
                <td><span class="badge badge-recruiting">Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            </tbody>
        </table>
        

            <div class="section-divider">Competitive Landscape</div>
            
        <table>
            <thead>
                <tr><th>Drug</th><th>Company</th><th>Mechanism</th><th>Stage</th><th>Efficacy</th><th>Differentiation</th></tr>
            </thead>
            <tbody>
                
            <tr>
                <td><strong>Evinacumab (Evkeeza)</strong></td>
                <td>Regeneron</td>
                <td>ANGPTL3 antibody</td>
                <td>Approved (HoFH)</td>
                <td>47% LDL-C reduction</td>
                <td style="font-size: 0.85rem;">Zodasiran shows higher efficacy (65% vs 47%), quarterly SC vs monthly IV</td>
            </tr>
            
            </tbody>
        </table>
        

            
            <div class="section-divider">Investment View</div>
            <div class="thesis-box thesis-bull">
                <div class="thesis-label">Bull Thesis</div>
                <p>ANGPTL3 is genetically validated - LOF mutations show low LDL, low TGs, reduced CV events. Zodasiran achieves dual LDL-C (65%) and TG (70%) reduction with quarterly dosing. Phase 3 HoFH trial recruiting.</p>
            </div>
            <div class="thesis-box thesis-bear">
                <div class="thesis-label">Bear Thesis</div>
                <p>Crowded lipid market with statins and PCSK9i. Evinacumab (Regeneron) already approved for HoFH. Quarterly injection vs daily statin limits adoption.</p>
            </div>
            <div class="thesis-box thesis-key">
                <div class="thesis-label">Key Question</div>
                <p>Can zodasiran demonstrate CV outcomes benefit to justify premium pricing?</p>
            </div>
            
        </div>
        
        <div class="section">
            <h2 class="section-title">Fazirsiran (ARO-AAT)</h2>

            <div class="grid-2" style="margin-bottom: 1.5rem;">
                <div>
                    <table>
                        <tr><td style="font-weight: 600; width: 120px;">Target</td><td>AAT (Alpha-1 Antitrypsin)</td></tr>
                        <tr><td style="font-weight: 600;">Stage</td><td>Phase 3</td></tr>
                        <tr><td style="font-weight: 600;">Indication</td><td>Alpha-1 Antitrypsin Deficiency Liver Disease (AATD-LD)</td></tr>
                        <tr><td style="font-weight: 600;">Modality</td><td>RNAi (siRNA)</td></tr>
                        <tr><td style="font-weight: 600;">Dosing</td><td>Subcutaneous Q12W (quarterly)</td></tr>
                    </table>
                </div>
                <div>
                    <h4 style="margin-bottom: 0.75rem;">Mechanism</h4>
                    <p style="font-size: 0.9rem; color: #475569;">Silences AAT mRNA, reducing both normal and mutant Z-AAT. Prevents accumulation of toxic aggregates in hepatocytes.</p>
                </div>
            </div>

            

            <div class="section-divider">Clinical Development</div>
            
        <table>
            <thead>
                <tr><th>NCT ID</th><th>Trial</th><th>Phase</th><th>Status</th><th>Result</th></tr>
            </thead>
            <tbody>
                
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT03946449" target="_blank">NCT03946449</a></td>
                <td>AROAAT-2002</td>
                <td>Phase 2</td>
                <td><span class="badge badge-completed">Completed</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">-96%</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT03945292" target="_blank">NCT03945292</a></td>
                <td>SEQUOIA Phase 2</td>
                <td>Phase 2</td>
                <td><span class="badge badge-completed">Completed</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT05677971" target="_blank">NCT05677971</a></td>
                <td>SEQUOIA Phase 3</td>
                <td>Phase 3</td>
                <td><span class="badge badge-recruiting">Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT05899673" target="_blank">NCT05899673</a></td>
                <td>SEQUOIA Extension</td>
                <td>Phase 3</td>
                <td><span class="badge badge-recruiting">Active Not Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            </tbody>
        </table>
        

            <div class="section-divider">Competitive Landscape</div>
            <p>No competitors listed.</p>

            
            <div class="section-divider">Investment View</div>
            <div class="thesis-box thesis-bull">
                <div class="thesis-label">Bull Thesis</div>
                <p>Fazirsiran addresses root cause of AATD liver disease by silencing mutant Z-AAT that aggregates in hepatocytes. Phase 2 showed 96% reduction with histological fibrosis improvement. No approved therapy exists. Takeda partnership provides $1B+ potential milestones.</p>
            </div>
            <div class="thesis-box thesis-bear">
                <div class="thesis-label">Bear Thesis</div>
                <p>AATD liver disease is rare (~10-15% of AATD patients). Regulatory path unclear - may require clinical outcomes not just Z-AAT reduction. Takeda controls development.</p>
            </div>
            <div class="thesis-box thesis-key">
                <div class="thesis-label">Key Question</div>
                <p>Will Phase 3 SEQUOIA show sufficient fibrosis improvement for FDA approval?</p>
            </div>
            
        </div>
        
        <div class="section">
            <h2 class="section-title">ARO-INHBE</h2>

            <div class="grid-2" style="margin-bottom: 1.5rem;">
                <div>
                    <table>
                        <tr><td style="font-weight: 600; width: 120px;">Target</td><td>INHBE (Inhibin beta E)</td></tr>
                        <tr><td style="font-weight: 600;">Stage</td><td>Phase 1/2</td></tr>
                        <tr><td style="font-weight: 600;">Indication</td><td>Obesity, Metabolic Dysfunction</td></tr>
                        <tr><td style="font-weight: 600;">Modality</td><td>RNAi (siRNA)</td></tr>
                        <tr><td style="font-weight: 600;">Dosing</td><td>Subcutaneous Q12W (quarterly)</td></tr>
                    </table>
                </div>
                <div>
                    <h4 style="margin-bottom: 0.75rem;">Mechanism</h4>
                    <p style="font-size: 0.9rem; color: #475569;">Silences INHBE which forms activin E. Activin E signals through ALK7 to promote fat accumulation. Blocking this shifts energy balance toward fat oxidation.</p>
                </div>
            </div>

            

            <div class="section-divider">Clinical Development</div>
            
        <table>
            <thead>
                <tr><th>NCT ID</th><th>Trial</th><th>Phase</th><th>Status</th><th>Result</th></tr>
            </thead>
            <tbody>
                
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT06700538" target="_blank">NCT06700538</a></td>
                <td>ARO-INHBE Phase 1/2</td>
                <td>Phase 1/2</td>
                <td><span class="badge badge-recruiting">Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">-6 to -9%</td>
            </tr>
            
            </tbody>
        </table>
        

            <div class="section-divider">Competitive Landscape</div>
            
        <table>
            <thead>
                <tr><th>Drug</th><th>Company</th><th>Mechanism</th><th>Stage</th><th>Efficacy</th><th>Differentiation</th></tr>
            </thead>
            <tbody>
                
            <tr>
                <td><strong>Semaglutide (Wegovy)</strong></td>
                <td>Novo Nordisk</td>
                <td>GLP-1 agonist</td>
                <td>Approved</td>
                <td>15-17% weight loss</td>
                <td style="font-size: 0.85rem;">ARO-INHBE is quarterly vs weekly, no GI side effects</td>
            </tr>
            
            <tr>
                <td><strong>Tirzepatide (Zepbound)</strong></td>
                <td>Eli Lilly</td>
                <td>GLP-1/GIP dual agonist</td>
                <td>Approved</td>
                <td>20-25% weight loss</td>
                <td style="font-size: 0.85rem;">Tirzepatide best-in-class efficacy</td>
            </tr>
            
            </tbody>
        </table>
        

            
            <div class="section-divider">Investment View</div>
            <div class="thesis-box thesis-bull">
                <div class="thesis-label">Bull Thesis</div>
                <p>Novel genetically-validated obesity target. INHBE LOF mutations associated with lower BMI. Early data shows 6-9% weight loss with quarterly dosing and no GI side effects (unlike GLP-1s). ARWR retains full rights.</p>
            </div>
            <div class="thesis-box thesis-bear">
                <div class="thesis-label">Bear Thesis</div>
                <p>GLP-1s achieving 15-25% weight loss are becoming standard of care. 6-9% may not be competitive. Mechanism less understood than GLP-1.</p>
            </div>
            <div class="thesis-box thesis-key">
                <div class="thesis-label">Key Question</div>
                <p>Can ARO-INHBE achieve &gt;15% weight loss to compete with GLP-1 agonists?</p>
            </div>
            
        </div>
        
        <div class="section">
            <h2 class="section-title">ARO-ALK7</h2>

            <div class="grid-2" style="margin-bottom: 1.5rem;">
                <div>
                    <table>
                        <tr><td style="font-weight: 600; width: 120px;">Target</td><td>ALK7 (ACVR1C)</td></tr>
                        <tr><td style="font-weight: 600;">Stage</td><td>Phase 1/2</td></tr>
                        <tr><td style="font-weight: 600;">Indication</td><td>Obesity, Metabolic Dysfunction</td></tr>
                        <tr><td style="font-weight: 600;">Modality</td><td>RNAi (siRNA)</td></tr>
                        <tr><td style="font-weight: 600;">Dosing</td><td>Subcutaneous (interval TBD)</td></tr>
                    </table>
                </div>
                <div>
                    <h4 style="margin-bottom: 0.75rem;">Mechanism</h4>
                    <p style="font-size: 0.9rem; color: #475569;">Silences ALK7 receptor in adipose tissue. ALK7 mediates activin E signaling that promotes fat accumulation.</p>
                </div>
            </div>

            

            <div class="section-divider">Clinical Development</div>
            
        <table>
            <thead>
                <tr><th>NCT ID</th><th>Trial</th><th>Phase</th><th>Status</th><th>Result</th></tr>
            </thead>
            <tbody>
                
            <tr>
                <td><a href="https://clinicaltrials.gov/study/NCT06937203" target="_blank">NCT06937203</a></td>
                <td>ARO-ALK7 Phase 1/2</td>
                <td>Phase 1/2</td>
                <td><span class="badge badge-recruiting">Recruiting</span></td>
                <td style="font-weight: 600; color: #0ea5e9;">Pending</td>
            </tr>
            
            </tbody>
        </table>
        

            <div class="section-divider">Competitive Landscape</div>
            <p>No competitors listed.</p>

            
            <div class="section-divider">Investment View</div>
            <div class="thesis-box thesis-bull">
                <div class="thesis-label">Bull Thesis</div>
                <p>ALK7 is receptor for INHBE/activin E - orthogonal approach to same pathway. Dual program gives optionality. Earlier stage means less dilution if successful.</p>
            </div>
            <div class="thesis-box thesis-bear">
                <div class="thesis-label">Bear Thesis</div>
                <p>Even earlier stage than ARO-INHBE. Same GLP-1 competition. May be redundant with ARO-INHBE.</p>
            </div>
            <div class="thesis-box thesis-key">
                <div class="thesis-label">Key Question</div>
                <p>Will ALK7 inhibition show differentiated profile vs ARO-INHBE?</p>
            </div>
            
        </div>
        
        
        <div class="section">
            <h2 class="section-title">Partnership Analysis</h2>

            <div class="grid-3" style="margin-bottom: 1.5rem;">
                <div class="card">
                    <div class="card-label">Total Partnerships</div>
                    <div class="card-value">3</div>
                </div>
                <div class="card">
                    <div class="card-label">Total Milestone Potential</div>
                    <div class="card-value">$3.3B</div>
                </div>
                <div class="card">
                    <div class="card-label">Received to Date</div>
                    <div class="card-value">$835M</div>
                </div>
            </div>

            <table>
                <thead>
                    <tr><th>Partner</th><th>Programs</th><th>Upfront</th><th>Milestones</th><th>Received</th><th>Royalties</th></tr>
                </thead>
                <tbody>
                    
            <tr>
                <td><strong>Amgen</strong></td>
                <td>Plozasiran, Zodasiran</td>
                <td>$35M</td>
                <td>$617M</td>
                <td>$120M</td>
                <td>Tiered, low double-digit</td>
            </tr>
            
            <tr>
                <td><strong>Takeda</strong></td>
                <td>Fazirsiran</td>
                <td>$300M</td>
                <td>$1040M</td>
                <td>$340M</td>
                <td>Tiered on net sales</td>
            </tr>
            
            <tr>
                <td><strong>Johnson &amp; Johnson (Janssen)</strong></td>
                <td>JNJ-3989 (ARO-HBV), JNJ-75220795 (ARO-HBV2)</td>
                <td>$250M</td>
                <td>$1600M</td>
                <td>$375M</td>
                <td>Mid-single to low-double digit</td>
            </tr>
            
                </tbody>
            </table>
        </div>
        
        
        <div class="section">
            <h2 class="section-title">Catalyst Calendar</h2>
            
            <div class="catalyst-item">
                <div class="catalyst-date">TBD</div>
                <div class="catalyst-event">
                    <div><strong>SHASTA-3 topline data</strong> <span class="badge badge-recruiting">Upcoming</span></div>
                    <div class="catalyst-asset">Plozasiran (ARO-APOC3)</div>
                    
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">TBD</div>
                <div class="catalyst-event">
                    <div><strong>SHASTA-4 topline data</strong> <span class="badge badge-recruiting">Upcoming</span></div>
                    <div class="catalyst-asset">Plozasiran (ARO-APOC3)</div>
                    
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">2026</div>
                <div class="catalyst-event">
                    <div><strong>SHASTA-3/4/5 Phase 3 data</strong> <span class="badge badge-recruiting">Upcoming</span></div>
                    
                    
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">2026-2027</div>
                <div class="catalyst-event">
                    <div><strong>Zodasiran Phase 3 HoFH data</strong> <span class="badge badge-recruiting">Upcoming</span></div>
                    
                    
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">2026-2027</div>
                <div class="catalyst-event">
                    <div><strong>Phase 3 HoFH data</strong> <span class="badge badge-recruiting">Upcoming</span></div>
                    <div class="catalyst-asset">Zodasiran (ARO-ANG3)</div>
                    
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">2028</div>
                <div class="catalyst-event">
                    <div><strong>SEQUOIA Phase 3 data</strong> <span class="badge badge-recruiting">Upcoming</span></div>
                    
                    
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">H1 2026</div>
                <div class="catalyst-event">
                    <div><strong>Plozasiran sHTG PDUFA</strong> <span class="badge badge-recruiting">Upcoming</span></div>
                    
                    
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">H1 2026</div>
                <div class="catalyst-event">
                    <div><strong>sHTG approval decision (PDUFA)</strong> <span class="badge badge-recruiting">Upcoming</span></div>
                    <div class="catalyst-asset">Plozasiran (ARO-APOC3)</div>
                    
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">2024</div>
                <div class="catalyst-event">
                    <div><strong>Phase 3 HoFH initiated</strong> <span class="badge badge-completed">Completed</span></div>
                    <div class="catalyst-asset">Zodasiran (ARO-ANG3)</div>
                    
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">2025-11-18</div>
                <div class="catalyst-event">
                    <div><strong>Plozasiran FCS approval</strong> <span class="badge badge-completed">Completed</span></div>
                    
                    <div style="color: #22c55e; font-size: 0.9rem;">Approved as REDEMPLO</div>
                </div>
            </div>
            
            <div class="catalyst-item">
                <div class="catalyst-date">2025-11-18</div>
                <div class="catalyst-event">
                    <div><strong>FCS approval (FDA)</strong> <span class="badge badge-completed">Completed</span></div>
                    <div class="catalyst-asset">Plozasiran (ARO-APOC3)</div>
                    <div style="color: #22c55e; font-size: 0.9rem;">Approved as REDEMPLO</div>
                </div>
            </div>
            
        </div>
        
        
        <div class="section">
            <h2 class="section-title">Valuation Framework</h2>

            <div class="grid-2">
                <div>
                    <h3 style="margin-bottom: 1rem;">Comparable Companies</h3>
                    <table>
                        <tr><th>Company</th><th>Market Cap</th><th>Lead Asset Stage</th></tr>
                        <tr><td>Alnylam (ALNY)</td><td>~$28B</td><td>5 Approved</td></tr>
                        <tr><td>Ionis (IONS)</td><td>~$8B</td><td>5 Approved</td></tr>
                        <tr><td>Arrowhead (ARWR)</td><td>~$4B</td><td>1 Approved</td></tr>
                    </table>
                </div>
                <div>
                    <h3 style="margin-bottom: 1rem;">Key Considerations</h3>
                    <ul style="margin-left: 1.5rem;">
                        <li>Platform value: Multiple Phase 3 programs</li>
                        <li>Partnership milestones: $3B+ potential</li>
                        <li>First approved product validates platform</li>
                        <li>Obesity programs if successful could be transformative</li>
                    </ul>
                </div>
            </div>

            <div class="thesis-box thesis-key" style="margin-top: 1.5rem;">
                <div class="thesis-label">Valuation Note</div>
                <p>Current valuation reflects approved FCS product and Phase 3 pipeline.
                Upside scenarios depend on sHTG approval (10x larger market) and obesity
                program success (multi-hundred billion market if competitive with GLP-1s).</p>
            </div>
        </div>
        
        
        <div class="section">
            <h2 class="section-title">Key Risks</h2>

            <div class="grid-2">
                <div class="card" style="border-left: 4px solid #ef4444;">
                    <div class="card-title">Commercial Execution</div>
                    <p style="font-size: 0.9rem; color: #64748b;">First commercial product launch.
                    Amgen partnership helps but ARWR has limited commercial track record.</p>
                </div>
                <div class="card" style="border-left: 4px solid #ef4444;">
                    <div class="card-title">Competition</div>
                    <p style="font-size: 0.9rem; color: #64748b;">Ionis Tryngolza (olezarsen) already
                    approved for FCS. Racing for sHTG market. GLP-1s dominating obesity.</p>
                </div>
                <div class="card" style="border-left: 4px solid #f59e0b;">
                    <div class="card-title">Partnership Dependency</div>
                    <p style="font-size: 0.9rem; color: #64748b;">Amgen and Takeda control late-stage
                    development and commercialization for key assets.</p>
                </div>
                <div class="card" style="border-left: 4px solid #f59e0b;">
                    <div class="card-title">Pipeline Concentration</div>
                    <p style="font-size: 0.9rem; color: #64748b;">Significant value tied to plozasiran
                    success. sHTG outcome critical.</p>
                </div>
            </div>
        </div>
        
        
        <div class="section">
            <h2 class="section-title">Data Sources</h2>

            <p style="margin-bottom: 1rem;">All data verified from authoritative sources.
            Last verification: 2026-02-02T19:30:00Z</p>

            <div class="section-divider">API Sources</div>
            
            <div style="margin-bottom: 0.5rem;">
                <strong>Fda Approvals</strong>:
                <a href="OpenFDA API (https://api.fda.gov/drug/drugsfda.json)" target="_blank">OpenFDA API (https://api.fda.gov/drug/drugsfda.json)</a>
            </div>
            
            <div style="margin-bottom: 0.5rem;">
                <strong>Clinical Trials</strong>:
                <a href="ClinicalTrials.gov API v2 (https://clinicaltrials.gov/api/v2/studies)" target="_blank">ClinicalTrials.gov API v2 (https://clinicaltrials.gov/api/v2/studies)</a>
            </div>
            
            <div style="margin-bottom: 0.5rem;">
                <strong>Company Info</strong>:
                <a href="Company website, SEC filings" target="_blank">Company website, SEC filings</a>
            </div>
            

            <div class="section-divider">Verified Clinical Trials</div>
            <p><a href="https://clinicaltrials.gov/study/NCT05089084" target="_blank">NCT05089084</a>, <a href="https://clinicaltrials.gov/study/NCT04720534" target="_blank">NCT04720534</a>, <a href="https://clinicaltrials.gov/study/NCT06347003" target="_blank">NCT06347003</a>, <a href="https://clinicaltrials.gov/study/NCT06347016" target="_blank">NCT06347016</a>, <a href="https://clinicaltrials.gov/study/NCT06880770" target="_blank">NCT06880770</a>, <a href="https://clinicaltrials.gov/study/NCT06822790" target="_blank">NCT06822790</a>, <a href="https://clinicaltrials.gov/study/NCT04998201" target="_blank">NCT04998201</a>, <a href="https://clinicaltrials.gov/study/NCT06347133" target="_blank">NCT06347133</a>, <a href="https://clinicaltrials.gov/study/NCT04832971" target="_blank">NCT04832971</a>, <a href="https://clinicaltrials.gov/study/NCT05217667" target="_blank">NCT05217667</a>...</p>

            <div class="section-divider">Additional Sources</div>
            <ul style="margin-left: 1.5rem; color: #64748b; font-size: 0.9rem;">
                <li><a href="https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001580063" target="_blank">SEC EDGAR Filings</a></li>
                <li><a href="https://ir.arrowheadpharma.com/news-releases" target="_blank">Company IR Page</a></li>
                <li><a href="https://www.accessdata.fda.gov/scripts/cder/daf/" target="_blank">FDA Drugs@FDA</a></li>
            </ul>
        </div>
        
    </div>
</body>
</html>